BioTuesdays

Tag - Brandon Folkes

Transgene-Logo
Markets

Cantor starts Transgene at OW; PT €4

Cantor Fitzgerald launch coverage of France-based Transgene (TNG:PA) with an “overweight” rating and a 12-month price target of €4. The stock was quoted at €2.01 on Feb. 17. “Our constructive view on Transgene stock is...

February 17, 2023
Markets

Cantor starts ObsEva at OW; PT $6

Cantor Fitzgerald launched coverage of ObsEva (NASDAQ:OBSV) with an “overweight” rating and a 12-month price target of $6. The stock closed at $1.96 on June 2. ObsEva is building a portfolio of best-in-class assets...

June 3, 2022
Journey Medical
Markets

Cantor starts Journey Medical at OW; PT $9

Cantor Fitzgerald initiated coverage of Journey Medical (NASDAQ:DERM) with an “overweight” rating and a 12-month price target of $9. The stock finished at $5.07 on Feb. 24. Journey is building a portfolio of commercial...

February 25, 2022
Collegium Pharma
Markets

Cantor ups Collegium Pharma to OW; PT to $26 from $17

Cantor Fitzgerald upgraded Collegium Pharmaceuticals (NASDAQ:COLL) to “overweight” from “neutral” and raised its price target to $26 from $17, citing its agreement to acquire BioDelivery Sciences International.  Shares...

February 14, 2022
AcelRx Pharma Logo
Markets

Cantor cuts AcelRx PT to $4 from $9; maintains OW

Cantor Fitzgerald reduced its price target for AcelRx Pharmaceuticals (NASDAQ:ACX) to $4 from $9, but maintained its “overweight” rating, citing a revised ramp in Dsuvia sales, as well as recent acquisitions and an...

December 2, 2021
Sanara MedTech Logo
Markets

Cantor starts Sanara MedTech at OW; PT $45

Cantor Fitzgerald launched coverage of Sanara MedTech (NASDAQ:SMTI) with an “overweight” rating and a 12-month price target of $45. The stock closed at $36.66 on June 29. Sanara has built a portfolio of differentiated...

June 30, 2021